<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146883</url>
  </required_header>
  <id_info>
    <org_study_id>B-ER-108-130</org_study_id>
    <nct_id>NCT04146883</nct_id>
  </id_info>
  <brief_title>Post-procedure Antibiotic Prophylaxis for Cardiac Electrical Device Implantation: ABxFREE Study</brief_title>
  <acronym>ABxFREE</acronym>
  <official_title>Post-procedure Antibiotic Prophylaxis for Cardiac Electrical Device Implantation: ABxFREE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center open-label randomized study, and we sought to investigate the
      redundancy of post-procedural prophylactic antibiotics in cardiac implantable electronic
      device implantation. There are 2 arms in this study. One arm will receive pre-procedural
      intravenous antibiotics only. The other arm will receive both pre-procedural intravenous
      antibiotics and post-procedural 3-day oral antibiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is general agreement on the benefits of preoperative prophylactic antibiotics which had
      been documented in previous studies. Concerns of bacterial resistance and unnecessary cost,
      our prospective observational case-control study had suggested the redundancy of
      post-procedural antibiotics. In this well-designed study, we sought to investigate the
      efficacy of post-procedural antibiotics and confirm the hypothesis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a multi-center, prospective, randomized and open-labeled study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac implantable electronic device related infection</measure>
    <time_frame>1 year</time_frame>
    <description>Any local and systemic signs/symptoms (pocket erosion, localized pocket erythema, swelling, heatness, pain, fever, bacteremia, lead/valvular vegetation) will be monitored during follow-up. The definition and classification of CIED related infection are based on the current guideline and expert consensus statement.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Post Procedural Infection</condition>
  <condition>Pacemaker Electrode Infection</condition>
  <condition>Antibiotics</condition>
  <condition>Implantable Defibrillator User</condition>
  <arm_group>
    <arm_group_label>Post procedural antibiotics treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group was treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin) and post procedural oral prophylactic antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre procedural antibiotics treatment only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group was only treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin</description>
    <arm_group_label>Post procedural antibiotics treatment</arm_group_label>
    <other_name>Cephalexin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for permanent pacemaker or implantable cardioverter defibrillator
             implantation according to current guidelines

        Exclusion Criteria:

          -  Hospitalization for more than 7 days

          -  End stage renal disease with hemodialysis or peritonealysis

          -  Patients receive cardiac resynchronization therapy, His-bundle pacemaker, leadless
             pacemaker, or sub-cutaneous implantable cardioverter defibrillator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ju-Yi Chen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung Univerity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui-Chen Chiang, Bachelor</last_name>
    <phone>+886-6-2353535</phone>
    <phone_ext>2388</phone_ext>
    <email>atiffany543783@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting-Chun Huang, MD</last_name>
    <phone>+886-6-2353535</phone>
    <phone_ext>2388</phone_ext>
    <email>dingean0723@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Chen Chiang, Bachelor</last_name>
      <phone>+886-6-2353535</phone>
      <phone_ext>2388</phone_ext>
      <email>atiffany543783@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Sandoe JA, Barlow G, Chambers JB, Gammage M, Guleri A, Howard P, Olson E, Perry JD, Prendergast BD, Spry MJ, Steeds RP, Tayebjee MH, Watkin R; British Society for Antimicrobial Chemotherapy; British Heart Rhythm Society; British Cardiovascular Society; British Heart Valve Society; British Society for Echocardiography. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemother. 2015 Feb;70(2):325-59. doi: 10.1093/jac/dku383. Epub 2014 Oct 29. Review.</citation>
    <PMID>25355810</PMID>
  </reference>
  <reference>
    <citation>Kusumoto FM, Schoenfeld MH, Wilkoff BL, Berul CI, Birgersdotter-Green UM, Carrillo R, Cha YM, Clancy J, Deharo JC, Ellenbogen KA, Exner D, Hussein AA, Kennergren C, Krahn A, Lee R, Love CJ, Madden RA, Mazzetti HA, Moore JC, Parsonnet J, Patton KK, Rozner MA, Selzman KA, Shoda M, Srivathsan K, Strathmore NF, Swerdlow CD, Tompkins C, Wazni O. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017 Dec;14(12):e503-e551. doi: 10.1016/j.hrthm.2017.09.001. Epub 2017 Sep 15. Review.</citation>
    <PMID>28919379</PMID>
  </reference>
  <results_reference>
    <citation>Lee WH, Huang TC, Lin LJ, Lee PT, Lin CC, Lee CH, Chao TH, Li YH, Chen JY. Efficacy of postoperative prophylactic antibiotics in reducing permanent pacemaker infections. Clin Cardiol. 2017 Aug;40(8):559-565. doi: 10.1002/clc.22698. Epub 2017 Apr 26.</citation>
    <PMID>28444977</PMID>
  </results_reference>
  <results_reference>
    <citation>Chiang KH, Chao TF, Lee WS, Lin YJ, Tuan TC, Kong CW. How Long Should Prophylactic Antibiotics be Prescribed for Permanent Pacemaker Implantations? One Day versus Three Days. Acta Cardiol Sin. 2013 Jul;29(4):341-6.</citation>
    <PMID>27122728</PMID>
  </results_reference>
  <results_reference>
    <citation>Madadi S, Kafi M, Kheirkhah J, Azhari A, Kiarsi M, Mehryar A, Fazelifar A, Alizadehdiz A, Emkanjoo Z, Haghjoo M. Postoperative antibiotic prophylaxis in the prevention of cardiac implantable electronic device infection. Pacing Clin Electrophysiol. 2019 Feb;42(2):161-165. doi: 10.1111/pace.13592. Epub 2019 Jan 4.</citation>
    <PMID>30575054</PMID>
  </results_reference>
  <results_reference>
    <citation>de Oliveira JC, Martinelli M, Nishioka SA, Varej√£o T, Uipe D, Pedrosa AA, Costa R, D'Avila A, Danik SB. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009 Feb;2(1):29-34. doi: 10.1161/CIRCEP.108.795906. Epub 2009 Feb 10. Erratum in: Circ Arrhythm Electrophysiol. 2009 Feb;2(1):e1. D'Avila, Andre [added].</citation>
    <PMID>19808441</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cheng-Kung University Hospital</investigator_affiliation>
    <investigator_full_name>Ju-Yi Chen</investigator_full_name>
    <investigator_title>Associate Professor, Department of Internal Medicine, College of Medicine, National Cheng Kung University</investigator_title>
  </responsible_party>
  <keyword>Prophylactic antibiotics</keyword>
  <keyword>Cardiac implantable electronic device infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will not share IPD due to the restriction of NCKUH IRB.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

